DNA-dependent RNA polymerase Inhibitors
2 drugsAbout DNA-dependent RNA polymerase
DNA-dependent RNA polymerase transcribes DNA into RNA, essential for gene expression in all organisms. Inhibiting this enzyme disrupts RNA synthesis, halting protein production and cell growth.
Currently, there is no genetic evidence directly linking RNA polymerase to specific diseases. However, its fundamental role in cell survival makes it a potential drug target.
Two FDA-approved drugs, RIFABUTIN and MYCOBUTIN, target RNA polymerase. Both are small molecules approved for 'other' therapeutic areas.
Top DNA-dependent RNA polymerase Drugs
The competitive landscape includes two companies, NOVITIUM PHARMA and Pfizer, with approved drugs.
Low competition suggests opportunity, but also consider potential barriers to entry or limited market size.
DNA-dependent RNA polymerase Drug Modality Landscape
Modalities
Routes of Administration
DNA-dependent RNA polymerase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like oligonucleotides to differentiate from existing small molecule drugs.
DNA-dependent RNA polymerase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DNA-dependent RNA polymerase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 13 | 2 | 0 | 87% |
| Phase 2 | 12 | 6 | 3 | 3 | 67% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 3 | 2 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
DNA-dependent RNA polymerase Drug Approval Timeline (1992 - 2014)
The first drug was approved in 1992, with the most recent in 2014, spanning 23 years.
Slow approval rate indicates a challenging target; assess reasons for past failures before investing.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 25 (11 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DNA-dependent RNA polymerase. A trial counts if an approved drug acting on DNA-dependent RNA polymerase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.